GE Healthcare (NYSE:GE) said today that it entered into a global commercial partnership with Theragnostics for its prostate-specific membrane antigen PET/CT imaging agent. The agreement stipulates that Theragnostics is to lead the development of the GalliProst diagnostic tracer, while GE Healthcare is slated to lead pre-approval commercial preparations, plus all commercial and distribution activities after […]